HACE1 Antibody [A17B18]

Catalog No.: F3628

For research use only.

    Home Primary Antibodies HACE1 Antibody [A17B18]

    Application: Reactivity:
    • F3628-wb
      Lane 1: HEK293, Lane 2: SH-SY5Y, Lane 3: Mouse brain, Lane 4: Rat brain

    Usage Information

    Dilution
    1:1000 - 1:10000
    Application
    WB
    Reactivity
    Mouse, Rat, Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    102 kDa 102 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.
    Positive Control Rat brain; Mouse brain; Human fetal brain; HEK293; SH-SY5Y; 293T
    Negative Control

    Exprimental Methods

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail)，and homogenize the tissue at a low temperature.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 5%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

    Datasheet & SDS

    Biological Description

    Specificity

    HACE1 Antibody [A17B18] recognizes endogenous levels of total HACE1 protein.
    Uniprot ID
    Q8IYU2
    Clone
    A17B18
    Synonym(s)
    KIAA1320, HACE1, E3 ubiquitin-protein ligase HACE1, HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1, HECT-type E3 ubiquitin transferase HACE1
    Background

    The HACE1 (HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1) gene is located on chromosome 6 and encodes a protein composed of 909 amino acids. HACE1 is strongly expressed in various human tissues, including the heart, brain, placenta, pancreas, and both fetal and adult kidneys. HACE1 mRNA is ubiquitously expressed across normal human tissues. Reduced expression levels of HACE1 are strongly associated with hypermethylation of two CpG islands located upstream of its gene locus, suggesting epigenetic regulation plays a role in its silencing. HACE1 is frequently downregulated in several types of cancer, including natural killer/T-cell lymphoma (NKTCL), colorectal cancer, and gastric cancer. Subcellularly, HACE1 localizes mainly to the endoplasmic reticulum and cytosol, although only low levels of endogenous protein are typically detected. Functionally, HACE1 acts as an E3 ubiquitin ligase and partners with the E2 enzyme UBCH7 to catalyze ubiquitination of target proteins. It is notably involved in phosphorylation-dependent degradation of cyclin D1, thereby playing a role in inhibiting cell cycle progression. HACE1 also preferentially binds to the active, GTP-bound form of the small GTPase Rac1 and promotes its polyubiquitination. This activity is essential for Rac1 degradation in response to cytotoxic necrotizing factor 1 (CNF1), facilitating bacterial invasion of endothelial cell monolayers, and highlighting a role for HACE1 in innate immune defense mechanisms. loss of HACE1 leads to the spontaneous development of late-onset tumors, further supporting its function as a tumor suppressor. The gene lies within the 6q21 chromosomal region which is a hotspot implicated in multiple human cancers, underscoring its clinical significance in tumorigenesis.
    References
    • https://pubmed.ncbi.nlm.nih.gov/34815381/
    • https://pubmed.ncbi.nlm.nih.gov/38364733/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.